source
- Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesTrodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.BioPharma Dive · 1mo ago↗ source
- Stealthy startup Treeline plans a reverse mergerLed by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.BioPharma Dive · 1mo ago↗ source
- FDA Expands Sunscreen Options for the First Time in 20 YearsToday, the U.S. Food and Drug Administration added bemotrizinol to the list of permitted sunscreen active ingredients, marking a significant milestone in the agency's efforts to advance sunscreen i…fda press